FDA Class II Recall: Contract Pharmacal's Acetaminophen Commingling Exposes OTC Supply Chain Risks
Contract Pharmacal Corporation faced an FDA Class II recall (D-0858-2020) for Major Extra Strength Acetaminophen Tablets due to commingling with a prenatal supplement. This event, now terminated, highlights critical quality control vulnerabilities in high-volume OTC manufacturing. Procurement directors and supply chain VPs must reinforce supplier qualification and audit processes to mitigate patient safety risks and ensure product integrity across their pharmaceutical portfolios.
FDA Class II Recall: Specifics of Contract Pharmacal's Acetaminophen Commingling Event
On February 3, 2020, Contract Pharmacal Corporation initiated a Class II recall, designated D-0858-2020, for Major Extra Strength Acetaminophen Tablets, 500 mg. This action was prompted by a critical quality deviation: the discovery of a women's prenatal dietary supplement tablet commingled within a 1000-count bottle of the Acetaminophen product. The affected batches included Lot #: 193005, with an expiration date of August 2021. For procurement directors, this incident underscores the severe implications of product commingling, which directly compromises product integrity and introduces significant patient safety risks, particularly for over-the-counter (OTC) medications like Acetaminophen, where consumer self-medication is prevalent. The recall specifically impacted 1176 bottles of the 100-count presentation (NDC 0904-6730-60; UPC 3 09046 73060 6) and 6,216 bottles of the 1000-count presentation (NDC 0904-6730-80; UPC 3 09046 73080 4), totaling 7,392 bottles distributed nationwide within the United States. This volume represents a substantial market exposure for Major Pharmaceuticals, the distributor, and necessitates a thorough review of quality assurance protocols at manufacturing and packaging sites.
Contract Pharmacal Corporation: Quality Control Challenges in OTC Manufacturing
Contract Pharmacal Corporation, identified as the recalling firm, operates from 135 Adams Ave, Hauppauge, NY 11788-3633. As a contract manufacturer, its role is pivotal in the supply chain for numerous pharmaceutical and dietary supplement brands. The commingling event involving Acetaminophen and a women's prenatal dietary supplement highlights a fundamental breakdown in segregation or packaging controls within their operations. For regulatory affairs heads and supply chain VPs, this incident with Contract Pharmacal Corporation serves as a critical reminder that even established manufacturers of high-volume, widely consumed OTC drugs are susceptible to significant quality lapses. Such errors can lead to product misidentification, potential allergic reactions, or adverse drug interactions, directly impacting consumer trust and brand reputation. Business development executives considering partnerships with contract manufacturing organizations (CMOs) must integrate robust quality audit frameworks into their due diligence, focusing specifically on cross-contamination prevention, line clearance procedures, and material handling protocols to safeguard product integrity across diverse manufacturing portfolios.
Supply Chain Vulnerability: Impact on Distributors and Patient Safety for Acetaminophen
The distribution of the affected Major Extra Strength Acetaminophen Tablets, 500 mg, was nationwide within the United States, managed by Major Pharmaceuticals, located at 17177 N. Laurel Park Drive, Suite 233, Livonia, MI 45162 USA. A Class II recall, as classified by the FDA, indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. In this specific case, the presence of a dietary supplement in an Acetaminophen bottle could lead to incorrect dosing, delayed treatment for pain or fever, or unintended exposure to ingredients in the prenatal supplement, which could be critical for individuals with specific allergies or medical conditions. For supply chain VPs, this event underscores the inherent risks associated with multi-product manufacturing environments and the critical need for stringent quality agreements with contract manufacturers and distributors. The financial implications of a recall, including retrieval costs, destruction, and potential legal liabilities, can be substantial, emphasizing the commercial imperative of preventing such quality failures at every stage of the supply chain.
Regulatory Resolution and Enhanced Procurement Due Diligence Post-Recall
The FDA recall D-0858-2020, initiated by Contract Pharmacal Corporation, was officially terminated on April 22, 2024. This 'Terminated' status signifies that the FDA has determined that all reasonable efforts have been made to remove or correct the product in question, and that the firm's corrective actions were deemed effective. While the immediate regulatory issue is resolved, the incident offers valuable lessons for procurement directors and regulatory affairs heads. It reinforces the necessity of continuous and rigorous supplier qualification and monitoring, particularly for contract manufacturing partners handling critical OTC products like Acetaminophen. Supply chain VPs should leverage such events to re-evaluate their risk assessment frameworks, ensuring that supplier audits go beyond initial qualification to include periodic assessments of quality management systems, segregation protocols, and the effectiveness of corrective and preventive actions (CAPA) implemented following any deviations. Proactive due diligence and robust quality agreements are paramount to building resilient supply chains and maintaining consumer confidence in pharmaceutical products.